Abstract: The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

Abstract: The use of carbamides as extractants for fully or partially separating uranium(VI) from plutonium(IV) in an aqueous solution obtained by dissolving a spent nuclear fuel in nitric acid, by method of liquid-liquid extraction, without carrying out any reduction of the plutonium(IV) to plutonium(III). The invention also relates to new carbamides. Uses are the processing of spent nuclear fuels based on uranium (especially uranium oxides—UOX) or uranium and plutonium (especially mixed uranium and plutonium oxides—MOX).

Abstract: The present invention comprises a method for the generation of 227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said 223Ra and 227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting 227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first 227Th solution containing contaminant 223Ra and 227Ac; v) loading the first 227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant 223Ra and 227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the 227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second 227Th solution.

Abstract: This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225Ac-HuM195.

Abstract: The present invention relates to a process for the oligomerisation of ethylene which comprises contacting ethylene with a transition metal-permethylpentalene complex, and a transition metal compound utilized therein.

Abstract: A filter element 12 that includes a fluid inlet 16, a fluid outlet 17 that is in fluid communication with the inlet 16, a filter media 40, 42 through which the fluid passes when moving from the inlet 16 to the outlet 17, and a plenum 38 that comprises continuous filaments 66 that are bonded to each other at points of filament intersection 68. The plenum is easy to manufacture, is resistant to compaction when contorted, and exhibits a low pressure drop as air is distributed across the filter media.

Abstract: The present invention is to provide the following: a material for hole injection transport layers and a production method thereof, the material capable of forming a hole injection transport layer by the solution application method and increasing device lifetime; an ink for forming hole injection transport layers and a production method thereof, the ink capable of forming a hole injection transport layer by the solution application method and increasing device lifetime; and a long-life device and a production method thereof; wherein disclosed is a material for hole injection transport layers, which is a reaction product of a molybdenum complex with a compound represented by the following chemical formula (i): wherein R1, R2, X1 and X2 are as explained in the Description.

Abstract: Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.

Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.

Abstract: It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Abstract: The present invention relates to per-substituted pentalene compounds, including permethylpentalene and precursors thereof. In particular, the invention provides substituted pentalene compounds and methods of preparing substituted pentalene compounds; complexes of metals with substituted pentalene compounds and methods for their production; and the use of complexes of metals with substituted pentalene compounds in catalysis.

Abstract: It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Abstract: The subject of the invention is a method of synthesizing a compound MxPy where M is an element belonging to one of columns II to XV of the Periodic Table of the Elements or to the family of lanthanides or to the family of actinides, characterized in that it includes the reaction of x moles of compound comprising the element M in its oxidation state 0 with y/4n moles of compound (P4)n. The method of the invention may be carried out at a temperature much lower than those necessary in the methods of the prior art. It also allows low-temperature formation of nanoparticles and stoichiometric reaction control. The applications of this method are numerous: magnetic ferro-magnets for MnP and FeP; hydrodesulfurization catalysts for Ni2P; luminescent nanoparticles for biological applications; microelectronics and optoelectronics for InP; and electronics for GaP. The latter two phosphides are also used in the photovoltaic energy field.

Abstract: Method of producing anhydrous thorium(IV) tetrahalide complexes, utilizing Th(NO3)4(H2O)x, where x is at least 4, as a reagent; method of producing thorium-containing complexes utilizing ThCl4(DME)2 as a precursor; method of producing purified ThCl4(ligand)x compounds, where x is from 2 to 9; and novel compounds having the structures:

Abstract: A ligand of Formula (I) is provided: wherein A4 represents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or —Z—Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, A4 cannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.

Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.

Abstract: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using amines and alkyl/aryl iodides are provided. The resultant carbon-isotope labeled amides are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.

Abstract: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with carbanion precursors pretreated by a base are provided. The resultant carbon-isotope labeled ketones, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided.

Abstract: Methods for generating an Ac-225 radioconjugate comprising a monoclonal antibody (mAb) (IgG) is disclosed. The Ac-225 radioimmunoconjugate is an [Ac-225]-p-SCN-Bn-DOT AIHuM195 radioimmunoconjugate.

Abstract: Disclosed herein is a method for the preparation of radioisotope-labeled compounds using CNT. It comprises filling the carbon nanotube with a radioisotope; and labeling a physiologically active material with the radioisotope charged in the carbon nanotube. Taking advantage of CNT, the method can prepare a radioisotope-labeled compound invention at a high yield and in a simple manner. Also, the radioisotope, when remaining unreacted, can be recovered by the filtration of the CNT, thereby achieving the prevention of radioactive contamination and the reduction of radioactive waste. Further, the radioisotope-labeled compound is useful as a contrast medium for imaging the hepatobiliary system.

Abstract: UI3(1,4-dioxane)1.5 and UI4(1,4-dioxane)2, were synthesized in high yield by reacting turnings of elemental uranium with iodine dissolved in 1,4-dioxane under mild conditions. These molecular compounds of uranium are thermally stable and excellent precursor materials for synthesizing other molecular compounds of uranium including alkoxide, amide, organometallic, and halide compounds.

Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.

Abstract: Method for producing terminal uranium nitride complexes comprising providing a suitable starting material comprising uranium; oxidizing the starting material with a suitable oxidant to produce one or more uranium(IV)-azide complexes; and, sufficiently irradiating the uranium(IV)-azide complexes to produce the terminal uranium nitride complexes.

Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.

Abstract: The invention relates to novel electropolymerisable monomers which are to be polymerised in an aqueous solution and comprise: an electropolymerisable pattern selected from acetylene, pyrrols, thiophenes, indols, anilines, azines, p-phenylene vinylenes, p-phenylenes, pyrenes, furanes, selenophenes, pyrridazines, carbazoles, acrylates, methacrylates and the derivatives thereof, and a metalloporphyrine which is substituted by at least two ionised or ionizable entities in an aqueous solution. The invention also relates to a method for the polymerization of such monomers, to the electroactive probe that can be obtained by the polymerization of such monomers, and to a method for detecting a target ligand in a biological sample using one such electroactive probe.

Abstract: Methods and reagents for synthesizing carbon-isotope labeled ketones and amines by carbonylation via Suzuki coupling reaction using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled ketones and amines are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.

Abstract: Method of producing anhydrous thorium(IV) tetrahalide complexes, utilizing Th(NO3)4(H2O)x, where x is at least 4, as a reagent; method of producing thorium-containing complexes utilizing ThCl4(DME)2 as a precursor; method of producing purified ThCl4(ligand)x compounds, where x is from 2 to 9; and novel compounds having the structures:

Abstract: A method for making a carbon nanotube metal composite includes the following steps. A number of carbon nanotubes is dispersed in a solvent to obtain a suspension. Metal powder is added into the suspension, and then the suspension agitated. The suspension containing the metal powder is allowed to stand for a while. The solvent is reduced to obtain a mixture of the number of carbon nanotubes and the metal powder.

Abstract: Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.

Abstract: A new class of heterocyclic metallocenes, a catalytic system containing them and a process for polymerizing addition polymerizable monomers using the catalytic system are disclosed; the heterocyclic metallocenes correspond to the formula (I): YjR?iZjjMeQkPl wherein Y is a coordinating group containing a six ? electron central radical directly coordinating Me, to which are associated one or more radicals containing at least one non-carbon atom selected from B, N, O, Al, Si, P, S, Ga, Ge, As, Se, In, Sn, Sb and Te; R? is a divalent bridge between the Y and Z groups; Z is a coordinating group, optionally being equal to Y; Me is a transition metal; Q is halogen or hydrocarbon substituents; P is a counterion; i is 0 or 1; j is 1-3; jj is 0-2; k is 1-3; and l is 0-2.

Abstract: Polymeric chelating agents and metal chelates, particularly those of lanthanide metals and more specifically those of Gd(III), useful as contrast agents in magnetic resonance imaging (MRI) for therapeutic and diagnostic applications as well as clinical and biomedical research applications. The polymeric chelates are generated using ring-opening metathesis polymerization (ROMP). Polymers can have multiple sites for functionalization allowing for the synthesis of multimodal and targeted contrast agents. Hydroxypyridonate (HOPO)-based chelating moieties are integrated into a ROMP-derived polymer. More specifically, the HOPO-based chelating moiety is integrated into a benzonorbornadiene unit that constitutes the backbone of the polymer. The ROMP-derived polymer chelators can comprise multiple metal ions, particularly Gd(III) ions, in polymers of varying lengths to provide a series of agents with controlled relaxivites. Polymer chelates include those that are water-soluble.

Abstract: The present invention provides a method for binding gaseous molecules, the method comprising contacting gases comprising the gaseous molecules with trivalent metal complexes. Typically, the gaseous molecules comprise polar molecules of greenhouse gases, especially the oxides of carbon, nitrogen and sulphur. Preferably, the trivalent metal complexes comprise complexes of actinide metals, most preferably uranium. The method is particularly useful in the removal of so-called greenhouse gases from the atmosphere, and is therefore of potentially very great value environmentally. The invention also provides trivalent metal complexes comprising sandwich complexes of trivalent metals selected from transition metals and actinide metals, the complexes comprising two ligands selected from pentalenyl, indenyl, cyclopentadienyl and cyclooctatetraene ligands. The invention further provides a method for the preparation of the trivalent metal complexes.

Abstract: The invention, in one aspect, relates to radiolabeled compounds. The invention also relates to radiolabeled liposomes and methods of making and using thereof. The invention also relates to kits for preparing radiolabeled liposomes.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with water pretreated by a base are provided. The resultant carbon-isotope labeled acids are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.

Abstract: Metal(IV) tetrakis(N,N?-dialkylamidinates) were synthesized and characterized. Exemplary metals include hafnium, zirconium, tantalum, niobium, tungsten, molybdenum, tin and uranium. These compounds are volatile, highly stable thermally, and suitable for vapor deposition of metals and their oxides, nitrides and other compounds.

Abstract: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.

Abstract: Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.

Abstract: An exemplary optical limiter device (100) has an optically transmissive substrate (102) and a layer (104) on a first surface (106) of the substrate, the layer having a trimetallic nitride endohedral metallofullerene. The layer can be a thin film of the trimetallic nitride endohedral metallofullerene, a layer material with a cavity containing a solution with the trimetallic nitride endohedral metallofullerene, a sol-gel with a trimetallic nitride endohedral metallofullerene, and a self assembled monolayer with a trimetallic nitride endohedral metallofullerene. The layers of trimetallic nitride endohedral metallofullerenes can be vapor deposited, solution deposited and/or self assembled onto optical components. The third-order nonlinear properties of these films provide desired transmission characteristics.

Abstract: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using weakly nucleophilic amines and alkyl/aryl iodides are provided. The resultant carbon-isotope labeled amides are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.

Abstract: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using amines and alkyl/aryl iodides are provided. The resultant carbon-isotope labeled amides are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.

Abstract: The invention relates to polyoxometalates represented by the formula (An)m+ [My(H2O)(p.y)X2W22O74(OH)2]m? or solvates or mixtures thereof, wherein A represents a cation, n is the number of the cations, m is the charge of the polyoxoanion, M represents a transition metal selected from Pd, Pt and mixtures thereof, y is 1, 2, 3 or 4, p is the number of water molecules bound to one M and varies from 3 to 5, and X represents a heteroatom selected from SbIII, BiIII, AsIII, SeIV and TeIV, a process for their preparation and their use for the catalytic oxidation of organic molecules.

Abstract: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailablity relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.

Abstract: A fluorous delivery or recovery material comprising a fluorous support material having a coating thereon, the coating comprising an amount of a fluorous reaction component that may be dispensed using non-gravimetric methods is disclosed. Also disclosed are methods for dispensing a fluorous reaction component comprising dispensing by non-gravimetric methods a predetermined amount of the fluorous reaction component as a coating on a fluorous support material.

Abstract: The present invention provides methods for separating isotopes of actinide elements such as uranium using microorganisms, e.g., metal or sulfate reducing bacteria. The microorganisms reduce the actinide element to form a precipitate, which contains a greater proportion of the lighter isotope relative to the heavier isotope than the starting material. The precipitate may be collected, re-oxidized, and subjected to multiple rounds of enrichment. Alternately, separation processes not requiring formation of a precipitate may be used. The invention also features cell-free systems for isotope separation.

Abstract: The present invention relates to a radionuclide-chitosan complex solution and its preparation method, and more particularly to the radionuclide-chitosan complex solution having a viscosity of 300˜2,400 cps, comprising an aqueous chitosan solution or a freeze-dried chitosan labeled with a radionuclide. The radionuclide-chitosan complex solution according to the present invention has a stable gelation state at a target region when injected into the body while maintaining a labeling yield of radioisotope to chitosan above 99%. Side effects may be minimized and treatment efficiency may be increased when injected to a patient.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.